ReviewMolecular biotechnology2009
Cell therapy for CNS trauma.
Review in Molecular biotechnology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Advances in gene and cellular therapeutic approaches for Huntington's disease.Protein & cell · 2025Review
- Current knowledge and challenges associated with targeted delivery of neurotrophic factors into the central nervous system: focus on available approaches.Cell & bioscience · 2021Review
- Cellular therapy for treatment of spinal cord injury in Zebrafish model.Molecular biology reports · 2021Review
- Gene transfer to rat cerebral cortex mediated by polysorbate 80 and poloxamer 188 nonionic surfactant vesicles.Drug design, development and therapy · 2018Article
- Neurobehavioural Toxicity of Iron Oxide Nanoparticles in Mice.Neurotoxicity research · 2017Article
- MSCs-Derived Exosomes and Neuroinflammation, Neurogenesis and Therapy of Traumatic Brain Injury.Frontiers in cellular neuroscience · 2017Review
- Development of a novel imaging system for cell therapy in the brain.Stem cell research & therapy · 2015Article
- Investigational agents for treatment of traumatic brain injury.Expert opinion on investigational drugs · 2015Review
- Current concept in neural regeneration research: NSCs isolation, characterization and transplantation in various neurodegenerative diseases and stroke: A review.Journal of advanced research · 2014Review
- Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery after spinal cord injury in mice.PloS one · 2011Article
- Screening genes related to development and injury of the mouse optic nerve by cDNA microarrays.Cellular and molecular neurobiology · 2010Article
- Angiogenesis, neurogenesis and brain recovery of function following injury.Current opinion in investigational drugs (London, England : 2000) · 2010Review
- Stem cells in human neurodegenerative disorders--time for clinical translation?The Journal of clinical investigation · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell therapy plays an important role in multidisciplinary management of the two major forms of central nervous system (CNS) injury, traumatic brain injury and spinal cord injury, which are caused by external physical trauma. Cell therapy for CNS disorders involves the use of cells of neural or non-neural origin to replace, repair, or enhance the function of the damaged nervous system and is usually achieved by transplantation of the cells, which are isolated and may be modified, e.g., by genetic engineering, when it may be referred to as gene therapy. Because the adult brain cells have a limited capacity to migrate to and regenerate at sites of injury, the use of embryonic stem cells that can be differentiated into various cell types as well as the use of neural stem cells has been explored. Preclinical studies and clinical trials are reviewed. Advantages as well as limitations are discussed. Cell therapy is promising for the treatment of CNS injury because it targets multiple mechanisms in a sustained manner. It can provide repair and regeneration of damaged tissues as well as prolonged release of neuroprotective and other therapeutic substances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.